糖皮质激素联合特布他林治疗慢阻肺急性加重期的价值-国际医学与数据杂志-CSCIED科技核心评价数据库-手机版

糖皮质激素联合特布他林治疗慢阻肺急性加重期的价值

The value of glucocorticoid combined with terbutaline in the treatment of acute exacerbation of COPD

ES评分 0 浏览量：601 下载量：0

DOI	10.12208/j.ijmd.20220155
刊名	国际医学与数据杂志 International Journal of Medicine and Data
年，卷(期)	2022, 6(4)
作者	师洪波*,
作者单位	山东省东明县胡庄卫生服务中心山东菏泽 ;
摘要	研究糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果与价值。方法选择2021年02月－2022年02月到本院治疗慢阻肺急性加重期患者104例，按照不同的治疗方式，分为实验组与对照组，分析两组治疗效果。结果实验组治疗效果50（96.15％）优于对照组治疗效果44（84.62％），P＜0.05；治疗前，两组患者血气各项指标（PaO2、PaCO2、PH值、呼吸困难评分）对比，P＞0.05；治疗后，两组患者血气各项指标（PaO2、PaCO2、PH值、呼吸困难评分）对比，实验组各项指标更优，P＜0.05；实验组心肺功能指标优于对照组，P＜0.05；实验组患者不良反应发生率2（3.85%）低于对照组9（17.31%），P＜0.05。结论运用糖皮质激素联合特布他林药物对慢阻肺急性加重期患者治疗，疗效显著，安全性高，可运用。
Abstract	Objective To study the effect and value of glucocorticoid combined with terbutaline in the treatment of acute exacerbation of COPD. Methods from February 2021 to February 2022, 104 patients with acute exacerbation of COPD were selected and divided into experimental group and control group according to different treatment methods. The treatment effects of the two groups were analyzed. Results the treatment effect of the experimental group was 50 (96.15%) better than that of the control group 44 (84.62%), P < 0.05; Before treatment, the blood gas indexes (PaO2, PaCO2, pH value, dyspnea score) of the two groups were compared, P > 0.05; After treatment, the indexes of blood gas (PaO2, PaCO2, pH value, dyspnea score) of the two groups were compared, and the indexes of the experimental group were better, P < 0.05; The indexes of cardiopulmonary function in the experimental group were better than those in the control group (P < 0.05); The incidence of adverse reactions in the experimental group 2 (3.85%) was lower than that in the control group 9 (17.31%), P < 0.05. Conclusion glucocorticoid combined with terbutaline is effective and safe in the treatment of patients with acute exacerbation of COPD.
关键词	糖皮质激素；特布他林；慢阻肺急性加重期；血气指标；心肺功能
KeyWord	Glucocorticoid; Terbutaline; Acute exacerbation of COPD; Blood gas index; Cardiopulmonary function
基金项目
页码	59-62

参考文献
相关文献

[1] 卢刚. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的预后效果分析[J]. 中国农村卫生,2021,13(10):87,89.

[2] 付群. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的临床效果[J]. 航空航天医学杂志,2021,32(10):1220-1222.

[3] 李云刚. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的临床效果分析[J]. 中西医结合心血管病电子杂志,2020,8(25):62,68.

[4] 马建翠,张云冲. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果[J]. 中国农村卫生,2020,12(4):77.

[5] 常利. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果[J]. 中国实用医药,2021,16(29):123-125.

[6] 刘漪杉. 探讨糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果[J]. 中国实用医药,2021,16(26):118-120.

[7] 吴捷,蔡博,张吟,等. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的临床效果观察[J]. 黔南民族医专学报,2021,34(4):261-262.

[8] 李国斌. 糖皮质激素联合特布他林治疗慢阻肺急性加重期效果[J]. 中国社区医师,2019,35(4):25,27.

[9] 孙静,王利平. 分析糖皮质激素联合特布他林治疗慢阻肺急性加重期的临床价值[J]. 北方药学,2020,17(4):43-44.

[10] 林宏超. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的疗效[J]. 中国处方药,2020,18(5):81-82.

引用本文

师洪波*. 糖皮质激素联合特布他林治疗慢阻肺急性加重期的价值 [J]. 国际医学与数据杂志. 2022; 6; (4). 59 - 62.

文献评论

相关学者

相关机构